非阿片止痛药新锐Latigo(LTGO.US)IPO拟最高募资2.88亿美元,Nav1.8抑制剂剑指福泰制药(VRTX.US)百亿市场

智通财经
Aug 04
【非阿片止痛药新锐Latigo(LTGO.US)IPO拟最高募资2.88亿美元,Nav1.8抑制剂剑指福泰制药(VRTX.US)百亿市场】智通财经APP获悉,在生物科技IPO以55%的平均回报率碾压AI板块、成为2026年美股最大赢家的背景下,又一家临床阶段生物制药公司加入了上市热潮。专注于非阿片类口服镇痛药开发的Latigo Biotherapeutics(LTGO.US)周一公布了IPO条款,计划以每股16至18美元的价格发行1,600万股,最高募资约2.88亿美元。按发行区间中点计算,这家总部位于加州千橡市的生物科技公司完全稀释后市值将达到约12亿美元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10